The Jharkhand market grew the highest, followed by Madhya Pradesh and Odisha
The Indian Pharma Market (IPM) has clocked Rs 6898 crores in October 2014. It has grown at 5.2 per cent in the said month. Amongst the top 10, GlaxoSmithKline Pharmaceuticals (GSK) grew by 12.8 per cent followed by Ranbaxy at 12.4 per cent and Mankind at 10.2 per cent. 27 corporate have crossed the growth of IPM amongst top 50. Amongst the top 50 corporates, Akumentis has the highest growth of 66.1 per cent followed by Ajanta at 22.9 per cent and Merck at 22.4 per cent. 15 corporates have shown growths more than 10 per cent amongst the top 50.
Amongst the 11-20 ranked corporates, Macleods has the highest growth of 22 per cent followed by USV at 16 per cent and Intas at 13.3 per cent. Amongst the 51-60 ranked corporates, Allergan has grown at 18 per cent followed by Troikaa at 13.3 per cent and Panacea at 12.5 per cent. Amongst the 61-75 ranked corporates, Boehringer grew by 59.5 per cent followed by East India at 14.5 per cent and Tablets India at 12.7 per cent.
Indian companies have grown at five per cent versus 5.7 per cent for MNCs in October 2014. Amongst the top 50 in MNCs, Merck grew by 22.4 per cent followed by GSK at 12.8 per cent and Ranbaxy at 12.4 per cent. Under the non-National List of Essential Medicines (NLEM) category Indian companies grew at 6.7 per cent whereas MNCs grew at 6.9 per cent.
With Bonus Units at Full Value | ||||||||
Val in Crs | Rank | MAT Oct -14 | Oct-14 | |||||
COMPANY | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 81103 | 100.00 | 9.6 | 6898 | 100.00 | 5.2 | ||
| Sun Pharma | 1 | 1 | 4373 | 5.39 | 14.4 | 376 | 5.46 | 8.5 |
| Cipla | 2 | 2 | 4069 | 5.02 | 11.2 | 349 | 5.06 | 9.5 |
| Zydus Cadila | 3 | 4 | 3175 | 3.91 | 7.6 | 262 | 3.80 | 1.6 |
| Ranbaxy | 4 | 3 | 2938 | 3.62 | 7.0 | 268 | 3.89 | 12.4 |
| Mankind | 5 | 5 | 2922 | 3.60 | 11.6 | 253 | 3.66 | 10.2 |
| Glaxo | 6 | 8 | 2761 | 3.40 | -7.0 | 224 | 3.25 | 12.8 |
| Lupin | 7 | 7 | 2721 | 3.36 | 12.7 | 225 | 3.26 | 5.2 |
| Abbott HC | 8 | 9 | 2690 | 3.32 | -0.5 | 218 | 3.15 | -9.1 |
| Alkem | 9 | 6 | 2612 | 3.22 | 14.0 | 230 | 3.33 | 3.9 |
| Pfizer | 10 | 11 | 2367 | 2.92 | 8.1 | 201 | 2.92 | 9.8 |
| Macleods | 11 | 10 | 2316 | 2.86 | 23.9 | 203 | 2.94 | 22.0 |
| Intas | 12 | 12 | 2120 | 2.61 | 15.6 | 190 | 2.75 | 13.3 |
| Aristo | 13 | 13 | 2039 | 2.51 | 20.6 | 183 | 2.66 | 9.9 |
| Sanofi India | 14 | 14 | 1979 | 2.44 | 0.4 | 169 | 2.44 | 2.8 |
| Torrent | 15 | 16 | 1772 | 2.18 | 4.9 | 141 | 2.04 | -5.1 |
| Glenmark | 16 | 15 | 1758 | 2.17 | 15.2 | 151 | 2.18 | 2.4 |
| Dr. Reddys | 17 | 17 | 1723 | 2.12 | 9.3 | 140 | 2.04 | 2.5 |
| Abbott | 18 | 19 | 1614 | 1.99 | 13.8 | 139 | 2.01 | 12.3 |
| Micro Lab | 19 | 21 | 1572 | 1.94 | 10.2 | 122 | 1.76 | -9.5 |
| USV | 20 | 18 | 1562 | 1.93 | 16.0 | 139 | 2.02 | 16.0 |
| Ipca | 21 | 20 | 1469 | 1.81 | 23.0 | 128 | 1.86 | 0.7 |
| Emcure | 22 | 22 | 1405 | 1.73 | 20.0 | 116 | 1.67 | 3.2 |
| Novartis | 23 | 23 | 1150 | 1.42 | 0.0 | 100 | 1.45 | 5.8 |
| Alembic | 24 | 24 | 1108 | 1.37 | 13.1 | 95 | 1.38 | 5.2 |
| Wockhardt | 25 | 25 | 995 | 1.23 | 6.1 | 80 | 1.16 | 3.3 |
The DPCO 2013 containing molecules market de-grew at -2.4 per cent whereas the non-DPCO market grew by 6.8 per cent resulting in an overall growth of 5.2 per cent for October 2014. NLEM and non-NLEM category showed negative unit growth at -5.7 per cent and -1.7 per cent respectively. The DPCO 2013 portfolio for Pfizer grew at 1.5 per cent, GSK 3.5 per cent, Ranbaxy 18.1 per cent.
From the therapy perspective, nine therapies have outgrown the IPM growth and five therapies have double digit growths. The respiratory market grew at 6.7 per cent, gastrointestinal market grew at 6.8 per cent, pain and analgesics market grew at 5.9 per cent whereas the anti-infectives grew at 3.3 per cent.
The anti-diabetic market grew at 13.5 per cent and the cardiac at 1.9 per cent in chronic business. The derma market grew by 10.3 per cent and the urology market at 21.1 per cent. From the regional perspective, 15 regions have outgrown the IPM growth. The Jharkhand market grew the highest at 20.4 per cent followed by the Madhya Pradesh market at 17.2 per cent and Odisha at 16.5 per cent. Five regions had negative growth in October 2014.
Amoxycillin + Clavulanic acid market grew at 5.9 per cent whereas Glimepiride + Metformin grew at 6.1 per cent at No 2.
Val in Crs | MAT Oct 14 | Month Oct-14 | ||
Super Group | Val in Crs | Val GR% | Val in Crs | Val GR% |
| IPM | 81103 | 9.6 | 6898 | 5.2 |
| ANTI-INFECTIVES | 13148 | 5.7 | 1153 | 3.3 |
| CARDIAC | 9994 | 9.0 | 821 | 1.9 |
| GASTRO INTESTINAL | 9309 | 11.0 | 769 | 6.8 |
| VITAMINS / MINERALS / NUTRIENTS | 7301 | 10.2 | 613 | 4.8 |
| RESPIRATORY | 6312 | 12.2 | 561 | 6.7 |
| ANTI DIABETIC | 6015 | 19.4 | 524 | 13.5 |
| PAIN / ANALGESICS | 5825 | 8.9 | 501 | 5.9 |
| NEURO / CNS | 5049 | 7.5 | 417 | 1.1 |
| DERMA | 4603 | 15.7 | 400 | 10.3 |
| GYNAECOLOGICAL | 4151 | 4.0 | 336 | 1.8 |
| OPHTHAL / OTOLOGICALS | 1478 | 12.5 | 132 | 17.0 |
| HORMONES | 1336 | 4.4 | 112 | 2.7 |
| ANTI-NEOPLASTICS | 1319 | 27.1 | 107 | 7.9 |
| VACCINES | 1144 | -8.2 | 89 | -6.2 |
| BLOOD RELATED | 973 | 2.2 | 76 | -9.3 |
| OTHERS | 879 | 7.7 | 76 | 10.9 |
| UROLOGY | 834 | 18.6 | 76 | 21.1 |
| ANTI MALARIALS | 615 | 9.2 | 70 | -0.8 |
| SEX STIMULANTS / REJUVENATORS | 454 | 2.4 | 35 | -5.3 |
| STOMATOLOGICALS | 365 | 11.7 | 30 | 3.2 |
The markets of paracetamol grew at 12.2 per cent, Atorvastatin 4.4 per cent, Azithromycin at 8.5 per cent, Probiotic Microbes at 20.6 per cent, Cefixime -5.9 per cent, Pantoprazole 5.7 per cent, Montelukast + Levocetrizine at 13 per cent, Glimepiride + Metformin + Pioglitazone at 17.2 per cent, Vitamin-D at 22.3 per cent, Hydroquinone + Mometasone + Tretinoin at 15 per cent, Voglibose + Metformin + Glimepiride at 39.2 per cent, Leveteracetam at 25.5 per cent.
Mixtard continues to lead the pack with Rs 29.5 crores for October 2014 with a growth of 12.2 per cent. Lantus grew at 26.8 per cent, Glycomet- GP grew at 25.2 per cent, Augmentin grew at 24.9 per cent, amongst the top 10 brands.
Amongst the brands who have gained ranks include Augmentin (+5), Glycomet-GP (+4), Lantus (+9), Dexorange (+6), Galvus Met (+12), Skinlite (+10), Spasmoproxyvon Plus ( +84), Pan (+11), Thyronorm (+19), Pan D ( +26), Jalra M (+48) amongst Top 100 Brands over October 2013.
Amongst the top brands in the IPM, Spasmoproxyvon Plus (116.9 per cent), Taxim (32.7 per cent), Galvus Met (31.6 per cent), Lantus (26.8 per cent), Glycomet – GP (25.2 per cent), Augmentin (24.9 per cent), PAN (24.2 per cent), Skinlite (22.6 per cent), grew fastest amongst the top 30 brands over October 2013.
A total of 167 brands were launched in October 2014.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
- Advertisement -